Single-agent therapy for acute pelvic inflammatory disease

Sulbactam/ampicillin versus cefoxitin

D. L. Hemsell, R. E. Bawdon, P. G. Hemsell, B. J. Nobles, M. C. Heard

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A total of 54 women with acute salpingitis were treated intravenously with ampicillin/sulbactam or cefoxitin in a prospective, randomized, ongoing study. Of the organisms isolated, Gram-negative species (excluding Neisseria gonorrhoeae) were considerably more likely to produce β-lactamase than were Gram-positive species. Clinical efficacy was 94% for 2 g ampicillin plus 1 g sulbactam and 89% for 2 g cefoxitin, all given intravenously every 6 h. The addition of sulbactam, an irreversible β-lactamase inhibitor, to ampicillin restored both the microbiological and clinical activities of ampicillin. Both regimens were equally safe and demonstrated good efficacy in the treatment of the acute, symptomatic phase of infection.

Original languageEnglish (US)
JournalJournal of International Medical Research
Volume18
Issue numberSUPPL. 4
StatePublished - 1990

Fingerprint

Cefoxitin
Pelvic Inflammatory Disease
Ampicillin
Sulbactam
Salpingitis
Neisseria gonorrhoeae
Therapeutics
Infection
sultamicillin

Keywords

  • acute pelvic inflammatory disease
  • ampicillin
  • cefoxitin
  • salpingitis
  • sulbactam

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Single-agent therapy for acute pelvic inflammatory disease : Sulbactam/ampicillin versus cefoxitin. / Hemsell, D. L.; Bawdon, R. E.; Hemsell, P. G.; Nobles, B. J.; Heard, M. C.

In: Journal of International Medical Research, Vol. 18, No. SUPPL. 4, 1990.

Research output: Contribution to journalArticle

Hemsell, D. L. ; Bawdon, R. E. ; Hemsell, P. G. ; Nobles, B. J. ; Heard, M. C. / Single-agent therapy for acute pelvic inflammatory disease : Sulbactam/ampicillin versus cefoxitin. In: Journal of International Medical Research. 1990 ; Vol. 18, No. SUPPL. 4.
@article{c657bbc477404bd6af1893cd167d5f8a,
title = "Single-agent therapy for acute pelvic inflammatory disease: Sulbactam/ampicillin versus cefoxitin",
abstract = "A total of 54 women with acute salpingitis were treated intravenously with ampicillin/sulbactam or cefoxitin in a prospective, randomized, ongoing study. Of the organisms isolated, Gram-negative species (excluding Neisseria gonorrhoeae) were considerably more likely to produce β-lactamase than were Gram-positive species. Clinical efficacy was 94{\%} for 2 g ampicillin plus 1 g sulbactam and 89{\%} for 2 g cefoxitin, all given intravenously every 6 h. The addition of sulbactam, an irreversible β-lactamase inhibitor, to ampicillin restored both the microbiological and clinical activities of ampicillin. Both regimens were equally safe and demonstrated good efficacy in the treatment of the acute, symptomatic phase of infection.",
keywords = "acute pelvic inflammatory disease, ampicillin, cefoxitin, salpingitis, sulbactam",
author = "Hemsell, {D. L.} and Bawdon, {R. E.} and Hemsell, {P. G.} and Nobles, {B. J.} and Heard, {M. C.}",
year = "1990",
language = "English (US)",
volume = "18",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Single-agent therapy for acute pelvic inflammatory disease

T2 - Sulbactam/ampicillin versus cefoxitin

AU - Hemsell, D. L.

AU - Bawdon, R. E.

AU - Hemsell, P. G.

AU - Nobles, B. J.

AU - Heard, M. C.

PY - 1990

Y1 - 1990

N2 - A total of 54 women with acute salpingitis were treated intravenously with ampicillin/sulbactam or cefoxitin in a prospective, randomized, ongoing study. Of the organisms isolated, Gram-negative species (excluding Neisseria gonorrhoeae) were considerably more likely to produce β-lactamase than were Gram-positive species. Clinical efficacy was 94% for 2 g ampicillin plus 1 g sulbactam and 89% for 2 g cefoxitin, all given intravenously every 6 h. The addition of sulbactam, an irreversible β-lactamase inhibitor, to ampicillin restored both the microbiological and clinical activities of ampicillin. Both regimens were equally safe and demonstrated good efficacy in the treatment of the acute, symptomatic phase of infection.

AB - A total of 54 women with acute salpingitis were treated intravenously with ampicillin/sulbactam or cefoxitin in a prospective, randomized, ongoing study. Of the organisms isolated, Gram-negative species (excluding Neisseria gonorrhoeae) were considerably more likely to produce β-lactamase than were Gram-positive species. Clinical efficacy was 94% for 2 g ampicillin plus 1 g sulbactam and 89% for 2 g cefoxitin, all given intravenously every 6 h. The addition of sulbactam, an irreversible β-lactamase inhibitor, to ampicillin restored both the microbiological and clinical activities of ampicillin. Both regimens were equally safe and demonstrated good efficacy in the treatment of the acute, symptomatic phase of infection.

KW - acute pelvic inflammatory disease

KW - ampicillin

KW - cefoxitin

KW - salpingitis

KW - sulbactam

UR - http://www.scopus.com/inward/record.url?scp=0025224112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025224112&partnerID=8YFLogxK

M3 - Article

VL - 18

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - SUPPL. 4

ER -